Mirion Technologies Inc Stock Price, News & Analysis

Mirion Technologies, Inc. (NYSE: MIR) has entered a definitive agreement to sell the physical medicine assets of Biodex Medical Systems, Inc. to Salona Global Medical Device Corporation for $5 million in cash and up to $3 million in deferred cash payments based on asset performance. These assets generated approximately $18 million in revenue with a gross margin of 30% in the last year. The deal is expected to close on December 31, 2022, allowing Mirion to focus on its core mission regarding ionizing radiation.

Mirion Technologies (MIR) reported third-quarter revenues of $160.9 million, an 11.5% increase from $144.3 million year-over-year. Despite this growth, the company faced a GAAP net loss of $50.4 million compared to a loss of $46.7 million in the prior year. Adjusted EBITDA decreased slightly to $30.8 million. Mirion anticipates organic adjusted revenue growth of 4% to 6% for 2022 alongside adjusted EBITDA guidance of $160 million to $170 million and adjusted EPS of $0.37 to $0.41. Year-to-date order growth stood at 23% with a $726 million backlog.

Mirion Technologies (NYSE: MIR) announced that CEO Thomas Logan and CFO Brian Schopfer will present at the 2022 Baird Industrial Conference in Chicago, IL. The presentation is scheduled for 11:50 AM ET on Thursday, November 10, 2022. A live webcast will be available at this link and will be archived for two weeks post-event.

Mirion is a premier provider of solutions for the nuclear, defense, medical, and research sectors, employing around 2,800 people globally.

Mirion Technologies (NYSE: MIR) announced it will release its financial results for Q3 2022 on November 1, 2022, after market close. The company will hold a conference call at 4:30 pm ET on the same day to discuss the results. Interested participants can join the call by dialing 1-877-407-9208 or 1-201-493-6784, or via a live webcast on the company's investor relations website.

Mirion is a leading provider of radiation detection and monitoring solutions, headquartered in Atlanta, GA, and operates in 13 countries with approximately 2,800 employees.

On October 21, 2022, Sun Nuclear, a subsidiary of Mirion Technologies (NYSE: MIR), announced its participation in the ASTRO Annual Meeting, showcasing its enhanced Quality Management portfolio. Key exhibits include the SunCHECK Platform and the new SunSCAN 3D System, designed for precise dosimetry and efficient workflows in radiation therapy. Sun Nuclear emphasizes its commitment to patient safety, supporting over 1,600 global clinical users with advanced QA solutions. The event runs from October 23-25, 2022, in San Antonio, Texas, where attendees can participate in demonstrations and networking sessions.

Sun Nuclear, a subsidiary of Mirion Technologies (NYSE: MIR), announced the development of new Quality Management solutions in collaboration with Accuray for the Radixact® System with Synchrony®. These innovations will be showcased at the ASTRO Annual Meeting from October 23-25, 2022. Key offerings include the Enhanced Dynamic Platform, designed for precise tumor treatment, and the MotionCHECK™ 3D System, enhancing tumor tracking capabilities. These tools aim to improve patient safety and quality assurance in advanced radiation therapy.

Mirion Technologies has appointed Michael Rossi as the new President of Mirion Medical, reporting directly to CEO Tom Logan. Rossi, with extensive experience from Novartis and other companies, aims to leverage his expertise in nuclear medicine to boost organic and inorganic growth within the company. Logan expressed confidence in Rossi's leadership abilities, highlighting the exciting growth opportunities ahead for Mirion. The company, headquartered in Atlanta, is a leading provider of radiation detection and analysis solutions, employing around 2,800 personnel across 13 countries.

Mirion Technologies, Inc. (NYSE: MIR) announced that its subsidiary, Sun Nuclear, achieved ISO/IEC 27001:2013 certification for its information security management system. This certification confirms Sun Nuclear's compliance with international standards for managing sensitive data across its facilities in the U.S., Germany, and the Netherlands. It also applies to the SunCHECK® Platform, enhancing software reliability and security. This distinction positions Sun Nuclear as a leading QA provider in the Radiation Oncology field, reinforcing its commitment to customer data protection.

Mirion Technologies, Inc. (NYSE: MIR) announces the appointment of Dr. Sheila Rege, M.D. to its Board of Directors, succeeding Mr. Christopher Warren. Dr. Rege, a board-certified radiation oncologist with over 30 years of experience, will support Mirion's strategy to enhance its Medical segment, aiming for 50% of total revenue. Chairman Lawrence D. Kingsley expressed confidence in her contributions to the company’s growth. Chris Warren leaves with commendations for his role in Mirion's evolution since 2015, emphasizing strong demand momentum in the market.